Nicotine pouches
Oral nicotine pouches, such as ZYN, are small tobacco-free sachets held between gum and lip. They avoid smoke and put almost no load on the lungs, but their alkaline chemistry delivers nicotine fast, their addiction potential is high, and their long-term effect on the heart is essentially unstudied.
Don't start using nicotine pouches if you don't already use nicotine. If you use them to get off cigarettes, treat them as a temporary step; varenicline, cytisine, combination nicotine replacement and nicotine e-cigarettes have the strongest evidence for quitting.
What they are
A pouch holds nicotine powder with fillers and flavourings but no tobacco leaf. How much nicotine reaches the blood depends on the pH: the more alkaline the pouch, the more nicotine is in its "free-base" form, which crosses the lining of the mouth quickly. US bench testing of 37 brands found about 1.3–6.1 mg of nicotine per pouch at a pH of about 6.9–10.1, with a large free-base fraction: the alkaline chemistry that maximises absorption.[1] Higher per-pouch figures cited elsewhere reflect broader global-market surveys. Trace nitrosamines are possible.
Fast growth, almost no long-term data
US unit sales of nicotine pouches rose several-hundred-fold between 2016 and 2020.[2] Studies document acute spikes in the sympathetic nervous system (the body's "fight or flight" response) after use, but durable effects on blood pressure, the heart or addiction have not been studied.[3] The American Heart Association states plainly that no data exist on the cardiovascular or health risks of these products.[4] That absence of evidence is not evidence of safety.
What long-term smokeless nicotine looks like
The closest long-term evidence comes from Swedish snus, a low-nitrosamine oral tobacco, which sits well below cigarettes but is not risk-free. A pooled analysis of eight Swedish cohorts of never-smoking men found that current exclusive snus users, compared with men who never used tobacco, had roughly 28% higher all-cause mortality and about 27% higher cardiovascular mortality, with a borderline rise in cancer deaths overall (about 12%); the risks grew with years of use but not with the amount used per week.[5] Pouches contain no tobacco, so the comparison is imperfect, but it shows that long-term oral nicotine use is not neutral. Nicotine itself also drives insulin resistance and is linked to metabolic syndrome and type 2 diabetes, and the ranking of nicotine products puts pouches roughly alongside vapes, well above patches.
Who should be careful
- Young people. The youth uptake curve is alarming, and adolescent nicotine exposure permanently changes the developing brain in animal studies.[6]
- Pregnancy. Obstetric guidance is to advise stopping tobacco products used in any form, e-cigarettes included; it does not address pouches specifically.[7]
- People with heart disease: caution seems prudent, given the acute sympathetic spikes and the lack of long-term data.
What to do
- If you don't use nicotine, don't start with pouches.
- If you smoke and want to quit, start with varenicline, cytisine, combination nicotine replacement or a nicotine e-cigarette; see Smoking and nicotine.
- If you use pouches already, plan to stop, and don't treat the lack of data as reassurance.
Further reading
- Stanfill S et al. Characterization of Total and Unprotonated (Free) Nicotine Content of Nicotine Pouch Products. Nicotine Tob Res 2021.[8]
- Marynak KL et al. Nicotine Pouch Unit Sales in the US, 2016-2020. JAMA 2021.[9]
- Dennison Himmelfarb CR et al. Impact of smokeless oral nicotine products on cardiovascular disease: a policy statement from the American Heart Association. Circulation 2025.[10]
- Byhamre ML et al. Swedish snus use is associated with mortality: a pooled analysis of eight prospective studies. Int J Epidemiol 2021.[11]